Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy

This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell carcinoma (ESCC) who achieve a complete or partial clinical response (cCR/cPR) following neoadjuvant immunochemotherapy.

Trial Details

NCT ID
NCT07629817
Phase
PHASE3
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy
  • Radiation with Concurrent Chemotherapy
  • Radical Esophagectomy
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Age 18-75 years, any sex.
  • ECOG Performance Status 0-1.
  • Histologically confirmed, previously untreated thoracic esophageal squamous cell carcinoma (ESCC).
  • Clinical stage cT2N0M0, T3N0-2M0 (AJCC 8th Edition), assessed as resectable with a potential for R0 resection by endoscopic ultrasound (EUS), PET-C…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →